Special Issue "Targeted Therapies for Melanoma"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (29 February 2020) | Viewed by 24005
Special Issue Editors

Interests: tumor microenvironment; cutaneous malignant melanoma; cancer-associated fibroblasts; squamous epithelium; stem cells
Special Issues, Collections and Topics in MDPI journals
Interests: skin biology; cell biology; keratinocyte; fibroblast; cancer microenvironment; immunohistochemistry; carcinoma; melanoma; inflammation; aging
Special Issues, Collections and Topics in MDPI journals
Interests: cell biology; tumour biology; oncology; melanoma; target therapy; immune-therapy; checkpoint inhibitors; skin tumours; cancer microenvironment
Special Issue Information
Dear Colleagues,
Malignant melanoma represents the most malignant type of skin cancer, with increasing incidence worldwide. Despite the remarkable progress in melanoma research and new therapeutic approaches, the therapy of the advanced stage of this tumor is still rather limited. Therefore, new ideas from basic research are an important input for translational and clinical research focusing on the intensification of the therapeutic strategies and specific targeting of melanoma. This Special Issue of Cancers aims to bring together the highest quality original/review articles on melanoma basic and clinical research. Papers focused on the molecular/cell biology of melanocyte to melanoma cell transition, melanoma ecosystems with the characterisation of melanoma microenvironments, mechanisms of metastatic spread and drug resistance, as well as articles analyzing recent experience with novel melanoma therapy and the development of new therapeutic approaches are invited.
Prof. Karel Smetana, Jr.
Dr. Lukas Lacina
Dr. Ondrej Kodet
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neural crest
- melanocyte
- melanoma stem cell
- melanoma microenvironment
- melanoma metastasis
- melanoma resistance to therapy
- melanoma therapy